August 2026– date –
-
Dual-Targeting Lipid Nanoparticles Drastically Enhance β Cell-Specific RNA Delivery, Promising for Type 1 Diabetes Therapy
ACS Publications USA Overview Researchers have developed a dual-targeting lipid nanoparticle (LNP) engineering strategy that significantly enhances β cell-directed RNA delivery. This novel LNP demonstrated substantially improved in vivo ... -
6th mRNA Therapeutics Summit Highlights Shift to Oncology, with In Vivo CAR-T, saRNA, and circRNA as Key Innovations
BioSpace USA Overview The 6th mRNA-Based Therapeutics Summit revealed a significant shift in mRNA clinical activity from infectious diseases to oncology, with in vivo CAR-T emerging as a notable application. Self-amplifying RNA (saRNA) a... -
New England Biolabs Unveils Comprehensive RNA Workflow Reagents Supporting mRNA Therapeutics and Diagnostics
New England Biolabs USA Overview New England Biolabs has announced an expanded portfolio of reagents to support various RNA research workflows, including mRNA therapeutics, personalized medicine, and diagnostics. The company highlights t... -
Schrödinger Unveils ‘Bunsen’ AI Co-Scientist to Accelerate End-to-End Biologics Discovery Workflow with BioLuminate and LiveDesign Integration
Schrödinger USA Overview Schrödinger is hosting an event to demonstrate an integrated, end-to-end workflow accelerating biologics discovery and engineering through BioLuminate and LiveDesign. A highlight of this session is the introducti... -
Generate Biomedicines’ AI-Designed Antibody GB-0895 Advances to Global Phase 3 for Severe Asthma; Insilico Medicine’s IPF Drug also Reaches Phase 3
Stock Titan USA Overview Generate Biomedicines announced its AI-designed anti-TSLP monoclonal antibody, GB-0895, has advanced to global Phase 3 clinical trials for severe asthma, highlighted in its Q2 2026 financial results. Novartis has... -
AI Drug Discovery Faces New Pain Points: Chemical Models Deliver Results, While Biological Models Struggle to Cross the ‘Valley of Death’
Moomoo USA Overview In AI-driven drug discovery, chemical models have successfully accelerated R&D by efficiently identifying targets and generating novel molecular structures. However, advancements in biological models still need to... -
AI Drug Discovery’s Core Challenge: Not Data Volume, But Converting Data into Actionable Clinical Evidence
MedCity News USA Overview The real challenge in AI-driven drug discovery is not the abundance of data, but the ability to transform that data into meaningful 'evidence' while preserving clinical context. Robust scientific and regulatory ... -
Insilico Medicine and Saudi Aramco Unveil sorbaMOF DB to Accelerate AI-Driven MOF Discovery for DAC Technologies
Unibest Industrial Co., Ltd. International Overview Insilico Medicine, in collaboration with Saudi Aramco, has launched 'sorbaMOF DB,' a validated materials database with an interpretable AI framework designed to accelerate the discovery... -
AI Biotechs Drive ‘Fail-Fast’ Drug Development in Biopharma, Powered by DeepMind’s AlphaFold
BioSpace USA Overview AI-centric biotechs like Isomorphic Labs and Generate Biomedicines are leveraging Google DeepMind's AlphaFold and proprietary 'dataverses' to propel a 'fail-fast' approach in drug discovery through in silico experim... -
AI-Driven CRISPR Design: Revolutionizing Gene Editing with Enhanced Precision and Efficiency
Preprints.org International Overview A comprehensive review systematically investigates AI-driven tools and methodologies for CRISPR design, highlighting AI's role in significantly enhancing gene editing precision, efficiency, and automa...
